Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CERTAIN-1: Cefepime-Taniborbactam vs Meropenem in cUTI
NCT03840148Phase 3Completed
- Sponsor
- Venatorx Pharmaceuticals
- Start
- Aug 2019
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 3 trial of taniborbactam in complicated urinary tract infection (cUTI), acute pyelonephritis, sponsored by Venatorx Pharmaceuticals. Started Aug 2019; status: completed.
02
Drugs
taniborbactam
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritis
Beyond the preview
Go deeper on NCT03840148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03840148.